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Aim: The aim of the present study was to investigate expression patterns of transcription factor NF-κB (p50 and p65), ER, 
PR, Her2/neu, Ki-67 and p53 in tumor tissue of patients with breast cancer (BC) and analyze correlation between these 
markers. Patients and Methods: 62 BC patients previously not treated with chemo- or radiotherapy were included in the 
study. All tumors belong to invasive ductal carcinoma of different grade. Expression of molecular markers was determined 
by immunohistochemical analysis on paraffin-embedded tissue sections. Results: The correlation between tumor grade and 
expression of ER, PR, Ki-67 and p53 was defined. NF-κB expression was found to be changed dependent on expression of ER, 
PR and p53 and also on molecular subtype (luminal, Her2-positive, hybrid, basal-like). The highest levels of NF-κB, Ki-
67 and p53 were found in Her2/neu+ and basal-like tumor subtypes. Conclusion: The increase of nuclear expression 
of NF-κB correlates with a decrease of expression of steroid hormone receptors (ER and PR), increase of p53 accumulation, 
and is associated with Her2-positive and basal-like tumor types.
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Breast cancer (BC) is by far the most frequent 
cancer in women, and the main cause of death in 35–
55 years old women. Despite the impro�ement of diag�
nostic methods and chemotherapeutic regimens o�erall 
5�year sur�i�al of patients significantly depends on the 
stage of disease and for the period 2000–2005 was 
56.2% in Ukraine and 88.0% in the USA [1].
Such clinical characteristics as age, menstrual sta�
tus, tumor size, lymph node status and morphological 
characteristics of the tumor (histological type, grade, 
lymphatic/�ascular in�asion) traditionally are the most 
important prognostic factors. Howe�er, in the last de�
cades understanding of tumor nature has been greatly 
impro�ed by molecular biology researches that allowed 
application of tumor’s molecular features for prognosis 
of the disease course. Most molecular markers that are 
studied today, determine the ability of cells to malig�
nant growth [2]. Estrogen and progesterone receptors 
(ER, PR) were the first predicti�e molecular markers 
for BC. Patients with positi�e status of these steroid 
hormone receptors generally ha�e high sensiti�ity 
to hormone therapy. Next marker that was included 
in clinical practice is HER2/neu, which positi�e status 
in patients with BC correlates with high sensiti�ity 
to targeted therapy with trastuzumab. The use of these 
markers in clinical practice contributed to indi�idual�
ization of treatment and choice of adequate chemo�
therapeutic schemes for patients. Howe�er, 25–50% 
of ER and PR positi�e tumors are resistant to hormone 
therapy [3], and tumors with Her2/neu o�erexpression 
not always respond to trastuzumab therapy. There are 
also about 20% of patients with BC negati�e by all three 
markers mentioned abo�e, and these tumors are more 
resistant to traditional therapy schemes.
Transcription factors may be considered as prom�
ising therapeutical targets because they affect the 
transcription of oncogenes that could play an important 
role in the formation of chemo�and radioresistance. One 
of the transcription factors dysfunction of which often 
occurs in malignant tumors, is a nuclear transcription 
factor NF�κB. NF�κB family is composed of polypep�
tides c�rel, p50, p52, p65 (RelA), p68 (RelB), p100 and 
p105, that belong to the rel�family proteins homologous 
to oncogene ��rel. The best studied of them are pro�
teins p50 and p65, which form the classic NF�kappaB 
heterodimer (p50/p65). In most cells, NF�κB is pres�
ent as a latent, inacti�e, IkB�bound complex in the 
cytoplasm. Under external stimuli, I�κB proteins are 
degraded �ia the ubiquitin�proteasome pathway, lead�
ing to release of the acti�e form of NF�κB that translo�
cates to the nucleus where it regulates the expression 
of target genes. NF�κB was disco�ered as a protein that 
specifically binds to a sequence of positi�e regulator 
of immunoglobulin’s κ light chain gene [4–6]. 
Further studies ha�e established the crucial role 
of NF�κB in the formation of immune response as well 
in processes of tumor de�elopment and growth. In many 
tumors (including BC, colon cancer, prostate cancer, 
lymphoid tumors, and probably many others) NF�
kB is constituti�ely acti�e and located in cancer cell 
nucleus [7]. NF�κB acti�ation is affected by a �ariety 
of inducers such as TNFα [8, 9], LPS [4, 6], PMA [4], 
interleukin�1 [10] and 2 [11], many �iruses [12, 13], hy�
drogen peroxide [14], ionizing radiation [15, 16] and oth�
ers. The time of NF�κB acti�ation �aries from 10 min for 
TNFα [4], up to 6 h for PMA [17] and is highly dependent 
on cell type. For re�inacti�ation NF�κB requires synthe�
sis of I�κB de novo that takes some time, so the action 
of acti�ated NF�κB can last up to 8 h [4]. One of the most 
important effects of NF�κB acti�ation is the blockade 
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of apoptosis. Classic inducer of NF�κB acti�ation is a tu�
mor necrosis factor (TNFα). TNFα may cause two op�
posite effects: on the one hand, it acti�ates cytotoxicity 
mechanisms that lead to cell death, on the other hand, 
indirectly acti�ates the transcription of genes which 
products can block apoptosis. NF�κB acti�ation plays 
a key role in pre�ention of TNF�induced apoptosis. TNFα 
is not the only agent capable to induce apoptosis and 
acti�ation of NF�κB. Similar processes can be induced 
by a majority of NF�κB acti�ators. It should be noted that 
the effect of NF�κB on apoptosis is highly dependent 
on many factors such as the type of inducer, cell type 
and functional status of the cell at a gi�en time, the pre�
sence of external influences on the cell and many others 
[18]. In many malignancies constituti�e le�el of NF�κB 
[19–21] is increased, at the same time, dysregulation 
of NF�κB in initially normal cell may lead to its malignant 
transformation [22, 23]. These and other data suggest 
an important role of NF�κB in cell proliferation and main�
taining the tumor cell �iability. This role has at least two 
important aspects. The first is that some oncogenes 
(c�myc), oncoproteins (p53) and onco�iruses are under 
the influence of NF�κB, or acti�ate it during malignant 
transformation (eg, ras). Another important point is the 
influence of NF�κB on tumor sensiti�ity to chemotherapy 
and immune reactions [24]. Action of many anticancer 
drugs, as well as most defense reactions is to induce 
apoptosis in cancer cells [25, 26]. At the same time, 
the acti�ation of NF�κB by these apoptosis inducers 
(TNFα, ionizing radiation, etc.) can protect cells from 
death. Montagut et al. [27] ha�e shown that acti�ation 
of NF�κB was significantly correlated with resistance 
to chemotherapy in BC patients. Furthermore, in some 
cases NF�κB acti�ation increased after chemotherapy 
exposure, which could cause the formation of drug 
resistance [27].
Also, correlation of NF�κB expression with other 
markers has been studied. The need for such studies 
is that the effect exerted by NF�κB on cell depends 
on the expression and functional status of many pro�
teins, for example, �ery complex and �aried interactions 
between NF�κB and p53, which can lead to opposite 
effects in different systems. One of the most important 
functions of p53 is induction of apoptosis in response 
to some signals, such as �iral infection or DNA dam�
age. Due to these properties p53 is considered a tumor 
suppressor what is shown in different models [28, 
29]. Many studies also ha�e shown that both p53 and 
NF�kB inhibit each other’s ability to stimulate gene 
expression and that this process is controlled by the 
relati�e le�els of each transcription factor. Expression 
of either wild�type p53 or NF�kB suppresses stimulation 
of transcription by the other factor. Howe�er, mutations 
in the p53 gene lead to loss of its ability to regulate 
the transcription and acti�ity of the targets (including 
NF�kB), which causes the loss of apoptotic proper�
ties. So, it is important to compare NF�κB expression 
with expression of other markers that may ha�e a sig�
nificant effect on the functional acti�ity of NF�κB. There 
are also many contradictions in the results of studies 
of NF�κB expression due to the absence of a standard 
method of determining the NF�κB acti�ation, and the 
differences in interpretation of results obtained by the 
same method. Howe�er, in BC patients most results 
suggest that NF�κB is acti�ated mainly in ER�negati�e 
and Her2/neu�positi�e tumors [27, 30–32]. These 
tumors usually possess high proliferati�e index, are 
of high grade and drug resistance. These data allow 
to propose that the acti�ity of NF�κB may affect the drug 
sensiti�ity of tumors, and that the possibility of regula�
tion the NF�κB acti�ity open a new features in therapy 
of tumors [33].
MATERIALS AND METHODS
62 patients with BC pre�iously not treated with 
chemo� or radiotherapy and cured in I�ano�Franki�sk 
Regional Oncology Dispensary (I�ano�Franki�sk, 
Ukraine) were included in the study. All tumors belong 
to in�asi�e ductal carcinoma of different grade. Clinical 
data of patients and tumor characteristics are shown 
in Table 1.
Table 1. Clinical data of patients and morphological characteristics of tumors
Parameter Number of cases (%)
Stage
I 4 (6.4)
II 40 (64.5)
III 7 (11.3)
IV 2 (3.2)
«X» 9 (14.5)
Axillary nodal status
+ 33 (53.2
- 29 (46.8
Tumor grade
1 8 (12.9)
2 32 (51.6)
3 16 (25.8)
“X” 6 (9.7)
Expression of molecular markers was determined 
by immunohistochemical approach on formalin�fixed 
paraffin�embedded 4 µm tissue sections. Antigen re�
trie�al was performed at temperature 98 °C for 30 min, 
endogenous peroxidase was blocked with 0.03% hy�
drogen peroxide for 5 min. Slides were then washed 
with Tris�buffered saline solution at pH 7.6 and incu�
bated for 30 min with the following primary antibodies: 
Estrogen Receptor α (Monoclonal Rabbit Anti�Human, 
RTU, clone SP1, Dako, Denmark), Progesterone 
Receptor (Monoclonal Mouse Anti�Human, RTU, 
clone PgR 636, Dako, Denmark), c�erbB2 (Poly�
clonal Rabbit Anti�Human, 1:1000, Dako, Denmark), 
NF�кB p50 (NLS) (Polyclonal Rabbit Anti�Human, 
1:200, sc114, Santa Cruz Biotechnology, USA), 
p�NF�кB p65 (Ser 536) (Polyclonal Rabbit Anti�
Human, sc�33020, Santa Cruz Biotechnology, USA), 
Ki�67 (Monoclonal Mouse Anti�Human, RTU, clone 
MIB�1, Dako, Denmark), p53 (Polyclonal Rabbit Anti�
Human, 1:100, RP 106, Diagnostic BioSystems, USA), 
Cytokeratin 5/6 (Monoclonal Mouse Anti�Human, 
RTU, clone D5/16 B4, Dako, Denmark). After rinsing, 
slides were incubated with HRP from FLEX detection 
system (Dako, Denmark) for 20 min, treated with DAB 
for 3 min and counterstained with haematoxylin. Slides 
were washed in tap water, dehydrated, and mounted 
with glass co�erslips.
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For interpretation the reaction with antibodies 
against ER, PR, p50 and p65 the H�score method was 
used. The score is obtained by the formula:
H= 3 x % of strongly stained nuclei + 2 x % of mode�
rately stained nuclei + % of weakly stained nuclei.
Expression le�el of marker with H>100 was classi�
fied as high, H=50�99 — moderate and H<50 — low.
Her2/neu expression le�el was determined 
by reaction with antibodies against HER2/neu. For 
interpretation the reaction such criteria were applied: 
0 (negati�e): no staining is obser�ed or membranous 
staining is obser�ed in less than 10% of the tumor 
cells. 1+ (negati�e): A faint/barely perceptible staining 
is detected in more than 10% of the tumor cells. The 
cells are stained in part of their membrane. 2+ (equi�o�
cal): A weak to moderate complete membrane stain�
ing is obser�ed in more than 10% of the tumor cells. 
3+ (positi�e): A strong complete membrane staining 
is obser�ed in more than 30% of the tumor cells. Tu�
mors with expression le�el 0 and 1+ considered HER2/
neu�negati�e, and with 2+ and 3+ — positi�e.
Proliferation le�el was determined by reaction with 
antibodies against Ki�67: 0 — no nuclear staining is ob�
ser�ed in tumor cells; 1 — nuclear staining is detected 
in 1–10% of the tumor cells; 2 — 11–20%; 3 — 21–50%; 
4 — >50%. In tumors with le�el of Ki�67 expression “0”, 
“1”, “2” proliferation le�el was considered as low; and 
with “3” and “4” — high. 
P53�status of tumors was determined by the le�el 
of accumulation in the nuclei of tumor cells. Negati�e 
(0) — nuclear staining is detected in less than 10% 
of the tumor cells; positi�e: 1 — 11–20; 2 — 21–50%; 
3 — 51–75%; 4 — > 75%.
To check basal cell origin the expression 
of CK 5/6 in tumors with three�negati�e phenotype 
(ER�/PR�/Her2�) was determined. The tumors with 
cytoplasmic staining of more than 10% of tumor cells 
were considered as three�negati�e basal; otherwise — 
three�negati�e non�basal. 
For statistical analysis of the data the SPSS pro�
gram was used. To identify the correlation, the Pearson 
coefficient of correlation was defined, and to �erify its 
�alidity χ2 test was used.
RESULTS
In the 62 tumors of BC patients, expression le�els 
of the following molecular markers were in�estigated: ER, 
PR, Her2/neu, Ki�67, р53 and NF�κB subunits (p50 and 
p65 proteins). 47 tumors (76%) were ER�positi�e (H > 10) 
and 15 (24%) — ER�negati�e (H≤10). PR�status was 
positi�e (H>10) in 43 cases (68%), and negati�e — 
in 20 (32%). The Her2/neu o�erexpression was identi�
fied in 25 tumors (40%), other 37 patients had negati�e 
Her2/neu status. The study of NF�кB (р50 та р65) 
expression ha�e shown high le�els of p50 (H > 100) and 
p65 (H > 100) in tumors, respecti�ely, in 39 (63%) and 
7 (11%) patients. It should be noted that all tumors with 
high expression of p65 had high le�els of p50.
Proliferati�e acti�ity of tumors was high (Ki�
67 > 20%) in 29 (47%) and low (Ki�67<20%) in 33 (53%) 
patients. p53 status in tumors was positi�e in 22 (35%) 
and negati�e in 40 (65%) patients. 
According to molecular profile, tumors of BC pa�
tients were di�ided according to the classification of Da�
�id J. Dabbs [34] (Table 2). Tumors with high expression 
of ER (H > 100) and negati�e Her2/neu status (0, 1+), 
regardless of PR expression were attributed to luminal 
A subtype. Tumors with negati�e HER2/neu status and 
low�intermediate expression of ER (H = 11–99) or nega�
ti�e ER status (H ≤ 10) with positi�e PR expression 
(H > 10) were attributed to luminal B subtype. Basal�like 
subtype tumors had negati�e ER� ( H≤ 10), PR� (H ≤ 10) 
and Her2/neu�status (0, 1+). To �erify the basal origin, 
samples of triple�negati�e tumors were stained for cy�
tokeratin 5/6. CK5/6+ tumors were attributed to three 
negati�e basal and CK5/6� — to triple�negati�e non�
basal. Her2/neu+ subtype is characterized by nega�
ti�e ER/PR status and Her2/neu hyperexpression. The 
remaining tumors with positi�e status of ER, PR and 
Her2/neu were referred to the hybrid luminal A/Her2/
neu or luminal B/Her2/neu subtype according to the 
le�el of ER/PR expression. Due to limited number 
of patients (n = 62), for statistical analysis such subtypes 
of tumors were included: luminal A and B — to luminal; 
triple�negati�e basal and non�basal — to basal�like; 
hybrid luminal A and B/Her2/neu+ — to hybrid luminal/
Her2/neu+ subtype [35]. So, after integration, the dis�
tribution of tumors by subtypes was as follows: tumors 
of 25 patients (40%) belonged to luminal subtype, 
12 (20%) — to basal�like, 7 (11%) — to Her2/neu+, 
18 (29%) — to hybrid (luminal/Her2/neu+) subtypes 
(Table 3). 
Table 2. Expression of molecular markers in BC
Experession of marker Number of cases (%)
ER
- 15 (24)
+ 47 (76)
PR
- 20 (32)
+ 42 (68)
Her2/neu
- 37 (60)
+ 25 (40)
р65 expression
Low 55 (89)
High 7 (11)
р50 expression
Low 23 (37)
High 39 (63)
Ki-67 expression
Low (< 20%) 33 (53)
High (> 20%) 29 (47)
р53
- 40 (65)
+ 22 (35)
The next relationships between clinical and mor�
phological characteristics of tumors and molecular 
markers expression were found: 1) the direct cor�
relation between tumor grade and proliferation index 
(Ki�67: r=1.0; p < 0.01); also, significantly increased 
accumulation of p53 was found in tumors with grade 
2 and 3 compared to grade 1 tumors (Fig. 1); 2) the 
in�erse correlation was between tumor grade and ER 
(significant correlation: r = �0.999; p < 0.05), PR (un�
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reliable correlation: r = �0.964; p = 0.086) (Fig. 1). 
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Fig. 1. Correlation between tumor grade and expression of Ki�
67 and p53 (a), ER and PR (b)
No relationship between expression of studied 
markers and clinical characteristics (age, stage, axil�
lary lymph node status) was found.
The in�erse correlation between expression of ste�
roid hormone receptors and: p50 expression (ER: 
p=�0.991, r<0.05; PR: p=�0.998, r<0.05); p53 ac�
cumulation (ER: p=�0.986, r=0.053; PR: p=�0.998, 
r<0.05) was found. The correlation between p65 and 
these markers was not significant.
The �ast majority of tumors with high expression 
of p50 and p65 were found to be ER (5 of 7) and PR 
(6 of 7) negati�e, while the percentage of ER� and 
PR� tumors was respecti�ely 24% and 32%. To study 
the relationship of markers expression and expression 
of NF�κB, we di�ided patients into 3 groups: I — with 
high le�els of p50 and p65 nuclear expression; II — 
with high p50 and low p65 le�els; III — with low le�els 
of p50 and p65. The in�erse correlation between ex�
pression of NF�κB and receptors of steroid hormones 
(ER: r=�1.0, p<0.01; PR: r=�0.999, p<0.05); and direct 
correlation between p53 accumulation and NF�κB ex�
pression (r=1.0, p<0.01) were found (Fig. 2).
Also the relation between NF�κB, p53, Ki67 ex�
pression and molecular profile of tumors was ana�
lyzed. Increase of NF�κB expression (p50: r=0.917, 
p<0.05; p65: r=0.974, p<0.05) in the direction of: 
Hybrid → Luminal → Basal�like → Her2/neu+ subtype 
was found (Fig. 3). These results are in contradiction 
to literature data [27, 30–32], according to which the 
lowest expression of NF�kB was obser�ed in luminal 
subtype, but this could be explained by a small cohort 
studied.
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Fig. 2. Correlation between expression of NF�kB and ER, PR and 
p53 in BC
Ki�67 proliferation index and p53 accumulation 
increased in this direction: Luminal → Hybrid → Basal�
like → Her2/neu+ subtype (Ki�67: r=0.928, p<0.05; 
p53: r=0.956, p<0.05) (Fig. 3).
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Fig. 3. Correlation between molecular subtype of BC and ex�
pression of p50 and p65 (a), and Ki67 and p53 (b).
So, summing up the results, we can say that NF�
kB expression is correlated with expression of markers 
Table 3. Molecular subtypes of breast cancer
Molecular subtype Criteria used for proposed categories Number of patients (%)
Luminal [15] Luminal А [14] ER 3+; Her2 0, 1+ 20 (32) 25 (40)
Luminal B [14] ER 1+, 2+; Her2 0, 1+; або ER 0; PR ≥ 1+; Her2 0, 1+ 5 (8)
Basal-like [15] Triple-negative basal [14] ER (H<30); PR (H<30); Her2 0, 1+; CK5/6 + 8 (13) 12 (20)
Triple-negative non-basal [14]2 ER (H<30); PR (H<30); Her2 0, 1+; CK5/6 - 4 (7)
Her2/neu+ [14, 15] ER (H<30); PR (H<30); Her2 2+, 3+ 7 (11)
Luminal-Her2/neu+ 
hybrid [15]
Luminal A-Her2/neu+ hybrid [14] ER 3+; Her2 2+, 3+ 12 (19) 18 (29)
Luminal B-Her2/neu+ hybrid [14] ER 1+, 2+; Her2 2+,3+; або ER 0; PR ≥1+; Her2 2+,3+ 6 (10)
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(ER, PR, p53, molecular profile of tumors) that predict 
the poor BC prognosis.
DISCUSSION
In this study we ha�e in�estigated the expression 
le�el of NF�κB subunits, and its relationship with clini�
cal and morphological parameters and the expression 
of other molecular markers. Being initially described 
as a crucial element in the formation of immune re�
sponse, presently NF�κB is considered also as a po�
tential target for cancer treatment. The possibility 
of this application of NF�κB is based on the fact that 
this transcription factor can inhibit apoptosis, stimulate 
cell proliferation, promote drug and radioresistance 
of cells. Howe�er, the effects of NF�κB acti�ation 
depend on many factors, including the expression 
of other proteins that can regulate its functional acti�ity. 
Another important point to consider in the study 
of NF�κB is that high expression of this factor is not 
always indicating its acti�ation. This comes up from the 
fact that normally NF�κB is located in the cytoplasm 
in an inacti�e, associated with the I�κB state, and only 
after acti�ation mo�es to the nucleus, where affects the 
transcription of target genes. In this work the expres�
sion le�el of NF�κB was determined by immunohisto�
chemical method, which allows taking into account 
location of protein in the cell with a high probability 
to speak about his acti�ation. Immunohistochemical 
study is also quite reliable method for detection the 
mutations in the p53 gene. According to the literature, 
positi�e p53 nuclear reaction in 90–100% of cases 
corresponds to missense�mutations in the p53 gene, 
which determines mutant immunophenotype [36]. 
The half�life of “wild type” p53 is up to 30 min due 
to rapid utilization in proteosome system, whereas 
mutant p53 has a lower affinity for proteins of this 
system, what increases its half�life to se�eral hours, 
and concentration to a le�el that can be determined 
by immunohistochemistry.
Summarizing the results we can say that the higher 
tumor grade correlates with a decrease of ER and 
PR expression, increase of proliferation index (Ki�67) 
and p53 accumulation. As for relationship between 
expression of NF�κB and other molecular, clinical and 
morphological features of BC, se�eral reported data 
are contradictory. According to our results, the highest 
le�els of NF�κB, Ki�67 and p53 were found in Her2/
neu+ and basal�like subtype of tumors that are associ�
ated with poor prognosis. The increase of nuclear ex�
pression of NF�κB correlates with a decrease of ER and 
PR expression and increase of p53 accumulation, that 
also worsens BC prognosis. These results are in agree�
ment with literature data about the drug resistance 
of tumors with positi�e p65 status [37].
Increased NF�κB expression is associated with 
molecular and physiological changes that contribute 
to its acti�ation. So, Her2/neu + and basal�like tumor 
subtypes generally ha�e a solid growth pattern and 
are associated with an increased inflammatory re�
sponse, which leads to increased le�els of hypoxia. 
The normal cellular response to hypoxia is go�erned 
by two dimeric transcription factors, hypoxia inducible 
factor�1 (HIF�1) and NF�kB. One of the effects of hy�
poxia is the degradation of I�kB and NF�kB acti�ation. 
NF�kB acti�ates signaling pathways that promote cell 
sur�i�al and angiogenesis. Regulator of these pro�
cesses is p53, which inhibits the acti�ation of HIF�1 and 
NF�kB. Mutations in the p53 gene leads to the loss 
of their ability to regulate the acti�ity of these factors 
that promote angiogenesis and tumor progression 
[38]. Using this logic, the inhibition of HIF�1 and/or NF�
kB can inhibit the angiogenic acti�ity of tumors, thereby 
curtailing their growth and metastases.
In conclusion, we ha�e re�eale correlation between 
expression le�els of ER, PR, Ki�67, p53 and BC grade, 
correlation between expression profile of NF�κB and 
expression le�el of ER, PR and p53. The highest le�els 
of NF�κB, Ki�67 and p53 were detected in Her2/neu+ and 
basal�like subtype of tumors. Our data allow to propose 
that acti�ated NF�κB in BC may indicate poor prognosis 
and de�elopment of drug resistance, howe�er, further 
research and retrospecti�e analysis performed on larger 
number of patients is required. 
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